HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

The Journal of Musculoskeletal Medicine Vol 28 No 5

Psoriatic Arthritis: Expanding Therapeutic Options

May 02, 2011

The therapeutic options for psoriatic arthritis (PsA) have expanded rapidly and improved patients’ pain, function, and quality of life. However, many patients do not respond to the current disease-modifying medications or cannot take them. Oral methotrexate is the leading disease-modifying antirheumatic drug used in PsA.

Understanding Allopurinol-Induced DRESS Syndrome

May 01, 2011

Drug-induced rash with eosinophilia and systemic symptoms (DRESS) syndrome may be triggered by numerous chemically unrelated medications. Allopurinol-induced DRESS (A-DRESS) syndrome carries the highest mortality risk.

Juvenile Arthritis Guidelines Focus on Multiple Medications

April 30, 2011

Clinical guidelines for the management of juvenile idiopathic arthritis (JIA) recently released by the American College of Rheumatology (ACR) focus on the initiation and safety monitoring of treatment with multiple medications.

Lifetime Risk of RA Higher Than Previously Thought

April 30, 2011

The lifetime risk of inflammatory autoimmune rheumatologic disease is substantial-1 in 12 for women and 1 in 20 for men, and the lifetime risk of rheumatoid arthritis (RA)-1 in 28 for women and 1 in 59 for men-is higher than previously thought.

Differentiating Lyme Arthritis From Septic Arthritis: Clues Uncovered

April 29, 2011

The prevalence of Lyme arthritis is high in pediatric patients who present with joint effusions in an area of the Northeastern United States in which the disease is endemic, and the disease is more common than septic arthritis.

Lupus Medication Trends: Immunosuppressives and Prednisone Linked With Disease Activity and Damage

April 29, 2011

Treatment for systemic lupus erythematosus (SLE) with both immunosuppressive agents and prednisone is given to patients who have the most active disease, but the presence of cumulative damage also may predict use of these agents, particularly early in the disease course.